A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT ID: NCT07218341
Last Updated: 2026-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE4
150 participants
INTERVENTIONAL
2026-03-31
2032-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
NCT06588478
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
NCT03740529
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pirtobrutinib (Arm A)
Participants receive pirtobrutinib orally
Pirtobrutinib
Administered orally
Idelalisib (Arm B)
Participants receive idelalisib orally
Idelalisib
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pirtobrutinib
Administered orally
Idelalisib
Administered orally
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mitchell Cancer Institute
Mobile, Alabama, United States
Arizona Oncology Associates, P.C. - HOPE
Tucson, Arizona, United States
Cancer Specialists, LLC
Jacksonville, Florida, United States
University of Maryland
Baltimore, Maryland, United States
Minnesota Oncology Hematology, P.A.
Coon Rapids, Minnesota, United States
Memorial Sloan-Kettering Cancer Center (MSKCC) - New York
New York, New York, United States
Oncology Hematology Care Inc
Cincinnati, Ohio, United States
Texas Oncology - Paris
Fort Worth, Texas, United States
US Oncology - Texas Oncology
Kyle, Texas, United States
Liverpool Hospital
Liverpool, , Australia
The Alfred Hospital
Melbourne, , Australia
LKH - Universitätsklinikum der PMU Salzburg
Salzburg, , Austria
AZ Delta
Roeselare, , Belgium
Queen Elizabeth II Health Sciences Center
Halifax, , Canada
Princess Margaret Cancer Centre - University Health Network
Toronto, , Canada
Xuanwu Hospital Capital Medical University
Beijing, , China
Sun Yat-sen University Cancer Center
Guangdong, , China
Nanfang Hospital of Southern Medical University
Guangzhou, , China
Gansu Provincial Cancer Hospital
Lanzhou, , China
The First Affiliated Hospital of Nanchang University
Nanchang, , China
Taizhou Hospital of Zhejiang Province
Taizhou, , China
Hematology Hospital of the Chinese Academy of Medical Sciences
Tianjin, , China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, , China
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, , China
The Affiliated Hospital of Xuzhou Medical College
Xuzhou, , China
Henan Cancer Hospital
Zhengzhou, , China
University Hospital Center Zagreb
Zagreb, , Croatia
Fakultni nemocnice Hradec Kralove
Hradec Kralove, , France
Centre Henri Becquerel
Rouen, , France
Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
Budapest, , Hungary
Debreceni Egyetem
Debrecen, , Hungary
St. James's Hospital
Dublin, , Ireland
Beaumont Hospital
Dublin, , Ireland
Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo
Alessandria, , Italy
Azienda Ospedaliera Universitaria Careggi
Florence, , Italy
Presidio Ospedaliero Papardo
Messina, , Italy
Fondazione IRCCS San Gerardo dei Tintori
Monza, , Italy
Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia
Perugia, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, , Italy
Tel Aviv Sourasky Medical Center
Tel Aviv, , Italy
Azienda Ospedaliera S. Maria Di Terni
Terni, , Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma
Verona, , Italy
Tokai University Hospital
Isehara, , Japan
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza
Brzozów, , Poland
Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy
Bydgoszcz, , Poland
Pratia Onkologia Katowice
Katowice, , Poland
Instytut Hermatologii I Transfuzjologii
Warsaw, , Poland
Hospital Universitario Marques De Valdecilla
Santander, , Spain
Hospital Universitario Virgen Del Rocio
Seville, , Spain
Castle Hill Hospital
Hull, , United Kingdom
St James's University Hospital
Leeds, , United Kingdom
GenesisCare
Newmarket, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J2N-MC-JZ03
Identifier Type: OTHER
Identifier Source: secondary_id
J2N-MC-JZNY
Identifier Type: OTHER
Identifier Source: secondary_id
27296
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.